Project Grant R01HL168579
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,340,904 to researchers at the University of Virginia (UVA) and the University of Manchester to investigate the role of interleukin-13 (IL-13) and hyaluronan (HA) in COVID-19 pathology. The researchers will determine how IL-13, which is elevated in COVID-19 patients, induces an HA matrix that recruits inflammatory cells and contributes to respiratory failure. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $480,990 to the University of Illinois to conduct research on the role of aerocytes, a recently identified capillary endothelial cell population, in regulating alveolar regeneration following lung injury. The research aims to establish the central role of aerocytes and the signaling molecule R-spondin3 in guiding regenerative alveolar remodeling, with the...
This Project Grant award, totaling $639,740, was provided by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) federal grant program. The research aims to explore the role of the CD38 enzyme and CD8 tissue resident memory (TRM) cells in the development of chronic lung fibrosis following viral pneumonia, including COVID-19. The primary awardee, the University of Virginia, will conduct studies to determine if targeting CD38 could mitigate age-associated chronic lung...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director provided $14,427,699 to New York University School of Medicine for the period of May 24, 2021 through May 23, 2022. The award was made under the Lung Diseases Research program (CFDA #93.838) to support the POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION INITIATIVE: NYU LANGONE HEALTH CLINICAL SCIENCE CORE, DATA RESOURCE CORE, AND PASC BIOREPOSITORY CORE....
This Project Grant award of $503,637 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms leading to thrombotic events and microclot formation in patients with COVID-19 infection. The primary objectives are to longitudinally assess changes in the hemostatic and fibrinolytic systems during acute COVID-19 infection and post-infection, determine the contributions of key regulatory proteins like protein S...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $690,626 to the Regents of the University of Michigan to study the role of type I interferon signaling in modulating acute lung injury and alveolar regeneration. The research aims to: 1) identify the molecular mechanisms linking interferon signaling to cell cycle arrest in respiratory epithelial cells, 2) determine if interferon signaling inhibits alveolar type 2 cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,659,996 to the University of Southern California (USC) to conduct research on the role of the protein PDLIM2 in regulating alveolar macrophages and their function in lung innate immunity, inflammation, and diseases. The key objectives are to determine the physiological and pathophysiological significance of the PDLIM2/CD80/PD-L1 signaling pathway in alveolar...
This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Oklahoma State University a $408,606 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to study the role of ERK1/2 signaling in SARS-CoV-2-induced dysregulated immunity and lung pathology. The 5-year project, which began on September 6, 2024, aims to demonstrate the critical role of myeloid cell TLR-ERK1/2 signaling in SARS-CoV-2-induced lung injury and pathology, investigate its impact on the...
The federal Project Grant award R35HL176572 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The $1,061,189 grant, awarded on January 1, 2025, supports research at the University of Michigan focused on immune crosstalk in lung injury and fibrosis. Key objectives include studying epithelial cell regulation of fibrosis, mechanisms for impaired innate immunity against gram-positive infections in fibrosis, and...